Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06177041
Status:
RECRUITING
Last Update Posted:
2024-02-28
First Post:
2023-12-11
Brief Title:
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin CLDN 182-Positive HER2-Negative PD-L1 CPS5 Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction GEJ Adenocarcinoma
Sponsor:
FutureGen Biopharmaceutical Beijing Co Ltd
Organization:
FutureGen Biopharmaceutical Beijing Co Ltd
Organization Data
Organization:
FutureGen Biopharmaceutical Beijing Co Ltd
Class:
INDUSTRY
Study ID:
FG-M108-04
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
FutureGen Biopharmaceutical Beijing Co Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None